New research suggests that people who stop using popular weight-loss injections like semaglutide or tirzepatide can put back on lost weight much more quickly than those who stop traditional lifestyle programs.
Research printed in a leading health publication demonstrates that while obese individuals can lose substantial amounts of their body weight while using the jabs, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing such treatments should be cognizant of the risk of quick weight regain when the treatment is stopped," warns lead investigator Dr. Susan Jebb.
That rate of regain implies a return to pre-treatment mass within about 18 months.
Weighing Therapies
The study, which reviewed dozens of studies involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with other pills.
The team emphasize that individuals who shed pounds through diet and exercise usually have a less rapid creep back—approximately 100 grams monthly—post-intervention.
The Reason for the Fast Regain
Nutrition scientists suggest the mechanism of the drugs accounts for the heightened regain.
These medications imitate a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Long-term administration of the hormone concentrations far above than normal may cause the body to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' leads to hunger is uncontrolled, making overeating a significant risk."
A Lifelong Issue?
The NHS suggest the jabs for individuals with weight-linked medical conditions, alongside recommended lifestyle changes.
A number of clinicians argue that, due to the significant potential of relapse, the treatment is often long-term.
This perspective is reinforced by drug manufacturers, who note that the results "emphasize the persistent character of excess weight," comparing it to managing diseases like diabetes.
Patient Testimonies
Individuals who have discontinued the medication report a intense resurgence of appetite.
"It was like a trigger activating and I was suddenly starving," said a patient.
This difficulty is compounded if users have not established lasting dietary or behavioural changes during therapy.
Growing Adoption
Survey data show that millions of people in the UK have used weight-loss jabs in the past year, with interest remaining high.
- Adoption is greater among women compared to men.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
In conclusion, experts emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a permanent cure and lasting health benefits hinges on integrated lifestyle changes.
